Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients
Manosuthi, W.; Kiertiburanakul, S.; Chaovavanich, A.; Sungkanuparph, S.
Journal of the Medical Association of Thailand 90(2): 244-250
2007
ISSN/ISBN: 0125-2208 PMID: 17375627 Document Number: 2725
Background. A fixed-dose combination of stavudine, lamivudine, and nevirapine (GPO-VIR) is the most affordable antiretroviral therapy (ART) regimen in Thailand The data of nevirapine (NVP) level and efficacy of this fixed-dose combination is limited.Material and Method. Patients who were initiated GPO-VIR in 2004 were enrolled NVP levels at 12 weeks were determined Patients were followed for 24 weeks.Results: Fifty-nine patients with a mean age of 36.4 years and 54% male were enrolled Mean body weight was 54.7 kgs. Median baseline CD4 and HIV-RNA were 29 cells/mm(3) and 2 70,000 (5.4 log(10)) copies/mL, respectively. Mean plasma NVP levels at 12 weeks was 6.4 mg/L. By linear regression, female gender (p = 0.042), and higher weight (p = 0.020) were associated with lower NVP levels. At 24 weeks, 78% achieved undetectable HI V-RNA and median CD4 was 156 cells/mm(3).Conclusion: NVP levels and 24-week efficacy of GPO-VIR are favorable. According to the affordable cost, GPO-VIR should be an appropriate initial regimen for naive HIV-infected patients in resource-limited settings.
Document emailed within 1 workday
